More than 1400 delegates from 17 countries took part in Russia’s top biotech conference Biomedical technologies industry in Russia has truly...
More than 1400 delegates from 17 countries took part in Russia’s top biotech conference
Biomedical technologies industry in Russia has truly been gaining momentum. To accomplish "Healthcare" National Project purposes and tasks, we should pay more attention to early-stage diagnosis.”
RUSSIA: 14 September 2018 -More than 1400 delegates from 17 countries took part in Russia’s top conference focusing on biotechnologies and pharmaceutical industry. More than 300 companies from all over the world took part in the exposition and business programme, which included 19 open panels and two closed meetings with 210 participating speakers.— Olga Piven, BIOTECHMED director
The forum’s exhibition consisted of 22 booths, while 33 partner companies presented state-of-the-art biomedical technologies. The programme also included press conferences of key participants of the plenary session, the Russian Export Center (REC); the presentation of the physiotherapeutic equipment for arterial blood pressure correction by Schwabe. "Startup-rally-2018" biomedical projects contest final was the closing event for Biotechmed 2018.
"BIOTECHMED is not only a space helping to establish a dialogue between the industry players, but also an exhibition site allowing to demonstrate the recent developments in pharmaceutical and medical industries, Russia's Minister of Industry and Trade Denis Manturov said. – The forum mainly focuses on biotechnologies that have been actively entering mass market medical services. They change the image of medicine and form radical competitive advantages globally. For example, an active introduction of advanced information technologies into the medical sphere can fit into the category, as well as personalized medicine development, post-genomic technologies, etc.", he added.
During his speech at the forum's plenary session that was dedicated to the national project on healthcare, Russia's Deputy Minister of Health Yevgeniy Kamkin noted: "One of the strategic targets of the development of the Russian Federation is to boost life expectancy to 78 years by 2024 and to 80 years by 2030. In accordance with the national targets, the country's Ministry of Health has developed "Healthcare" National Project passport, which includes eight federal projects".
BIOTECHMED has been actively developing and has seen the number of its visitors doubling during the three years of its existence. The event is traditionally held with the support from the Ministry of Health of the Russian Federation, the Ministry of Industry and Trade of the Russian Federation, Rostec State Corporation, Krasnodar Territory Administration. Russian Export Center is the general partner, JSC National Immunobiological Company is the strategic partner of the forum.
"We think that the level of attention to the forum, the number of delegates present at the venue and the number of federal and regional media covering the event show that biomedical technologies industry in Russia has truly been gaining momentum. To accomplish "Healthcare" National Project purposes and tasks, we should pay more attention to early-stage diagnosis. The whole medical industry focuses on that. Most medical devices and medications that were presented at Biotechmed 2018 are also mostly designed for early-stage diagnosis and preventive treatment", said Olga Piven, Biotechmed director, while summarizing the forum results.
"Project workshops were held in June as part of the Russian Export Center, where the support measures plan was drawn up. These measures will become a part of the national project to support exports and will allow us to achieve the targets mentioned by the Russian President Vladimir Putin in his May decrees. Let me remind you that according to these decrees the pharmaceutical products export is to reach $2.8 billion by 2024, while medical devices export is to double. The main problem of Russia's pharmaceutical industry is the complexity and high costs of testing abroad to obtain international certificates, which allow shipping the products abroad. We are preparing a set of measures which will let the companies use the financial support measures with utmost effectiveness to fulfil these tests", said Irina Kashirina, REC Head of the medical and pharmaceutical industry export support project during the press conference.
Among partners of the forum are Russian Venture Company; BIOCAD biotechnology company; Prospective Technologies Development Center; Techmash; Schwabe; National Center of Informatization; Takeda Russia; JSC Pharmasyntez; Pharmaclon; Siemens Helthineers; MSD; State Research Institute of Highly Pure Biopreparations, Russia's FMBA; IRVIN 2 LLC; Diaprocess LLC; JSC POZiS; Geropharm.
More than 1,500 experts from 52 regions and more than 300 companies took part in BIOTECHMED 2017 forum. JSC National Immunobiological Company; JSC Schwabe; LLC NCI; JSC POZiS; JSC Pharmasintez; Skolkovo Foundation; OOO MERK; ZAO BIOCAD; Russian Helicopters; NP Biotechnology of the Future; Novaya Meditsina LLC (DOC +); Marathon Pharma; Konversiya NPO; NIPK Elektron; NPP Pharmaclon; ChemRar; ELTA Company and GRPZ became BIOTECHMED forum partners.